Aprea Therapeutics (APRE) vs Kiora Pharmaceuticals (KPRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Aprea Therapeutics is the larger company by market cap ($3.2 million vs $3.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | APRE | KPRX |
|---|---|---|
| Share price | $0.229 | $0.7202 |
| Market cap | $3.25M | $3.19M |
| 1-day change | -53.56% | -12.28% |
| YTD return | — | -63.44% |
| 1-year return | — | -61.49% |
| 5-year return | — | -99.87% |
| EPS (TTM) | $-0.57 | $-2.72 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $0 |
| Revenue growth (YoY) | — | -100.00% |
| Net income (latest FY) | $-12.60M | $-10.84M |
| 52-week high | $1.49 | $2.91 |
| 52-week low | $0.2036 | $0.72 |
| Distance from 52-week high | -84.63% | -75.25% |
| Analyst consensus | none | none |
| Avg. price target upside | +1528.82% | +1566.20% |
| Average volume | 388.67K | 35.23K |
| Shares outstanding | 14.19M | 4.42M |
| Employees | 8 | 13 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Aprea Therapeutics
APRE stock →Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications.
Health Care · Biotechnology: Pharmaceutical Preparations · 8 employees
About Kiora Pharmaceuticals
KPRX stock →Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees
APRE vs KPRX FAQ
Which is bigger, Aprea Therapeutics or Kiora Pharmaceuticals?
Aprea Therapeutics (APRE) is larger, with a market capitalization of $3.25M compared with $3.19M for Kiora Pharmaceuticals (KPRX).
Are Aprea Therapeutics and Kiora Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.